Carlos Arthur Fernandes Sobreira

Carlos Arthur Fernandes Sobreira

Auto-generated profile, based on publicly available information

Carlos Arthur Fernandes Sobreira

Centro Universitário Christus (UniChristus), Brasil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021
Verified
Conference Paper
Closed access
CSCarlos Arthur Fernandes Sobreira
Carlos Arthur Fernandes Sobreira
BGBárbara Silva Gomes
Bárbara Silva Gomes
RARidson Guilherme Parente de Aguiar
Ridson Guilherme Parente de Aguiar
EREderson Aragão Ribeiro
Ederson Aragão Ribeiro
Publicado em 19/05/2021 - ISBN 978-65-5941-206-8 - Unichristus

14 February 2023 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
MRMarllan Louise Matos Rodrigues
Marllan Louise Matos Rodrigues
CSCarlos Arthur Fernandes Sobreira
Carlos Arthur Fernandes Sobreira
COClara Farias Otoni
Clara Farias Otoni
LALygia Gomes de Alencar Araripe
Lygia Gomes de Alencar Araripe
MMMelissa Soares Medeiros
Melissa Soares Medeiros
Patients with HIV infection may have different causes and manifestations for kidney disease, from subclinical proteinuria to acute renal failure. It can be caused both by the direct effect of HIV on the kidneys and by the nephrotoxic effect of antiretroviral medications. The objective of this study is to evaluate renal dysfunction and relate it to the glomerular filtration rate (GFR) of patients followed up in a reference outpatient clinic for patients living with HIV/AIDS (PLWHA). This is a cross-sectional, retrospective, non-interventionist study, carried out by reviewing the medical records of patients treated from 2017 to 2020, at the HIV outpatient clinic of a reference quaternary hospital in Fortaleza, Ceará, Brazil. The results evaluated 77 patients, aged between 32 and 77 years, 63.6% male and 35.1% female, in addition to 1.3% transsexual (N=1). 113 measurements of renal function markers were analyzed and correlated with the calculation of glomerular filtration rate (GFR) through age and the creatinine value by the MDRD GFR equation, with 32.7% (N=37) with normal GFR. The mean MDRD was 81.7 mL/min/1.73m2, mean protein/creatinuria ratio 0.16 (N=69) and mean beta2microglobulin of 2.4 ng/ml, with 60.5% of altered dosages (> two). Most frequent comorbidities: Diabetes mellitus (27.3%), SAH (22%), Dyslipidemia (28.6%) and kidney disease 14.3%). The preferred regimen, tenofovir, lamivudine and dolutegravir, was used by 33% of patients; 5.4% followed a simplified scheme with lamivudine and dolutegravir. Detectable viral load found in 9.8% of records. We conclude that patients have a high prevalence of kidney disease in PLWHA that correlate with the presence of comorbidities and tubular changes.

1 January 2024 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
MMMariana Rolim Fernandes Macedo
Mariana Rolim Fernandes Macedo
CSCarlos Arthur Fernandes Sobreira
Carlos Arthur Fernandes Sobreira
CLCarola Braz de Lavor
Carola Braz de Lavor
CRCamila Ribeiro Rôla
Camila Ribeiro Rôla
TRTiciana Maria de Lavor Rolim
Ticiana Maria de Lavor Rolim
ALAnna Sara Levin
Anna Sara Levin
Backgrounds: Fortunately, much has been studied about COVID-19 in patients with inflammatory bowel diseases (IBD). Evidence suggests that these patients do not appear to be at increased risk of severe COVID-19. However, there are still some uncertainties regarding the clinical manifestations of COVID-19 in patients with immune-mediated diseases. Objective: This study aimed to describe the main symptoms of COVID-19 and their frequency in IBD patients and evaluate the impact of the IBD therapeutic drugs on clinical presentation of COVID-19 and to determine factors associated with COVID-19 in this population. Methods: Adult patients with IBD from three tertiary-care public, teaching hospitals in Ceará, Northeastern Brazil, were evaluated during one scheduled appointment from March to December 2020. Patients with possible or confirmed COVID-19 were compared with patients without COVID-19. Furthermore, incidences of each symptom were evaluated based on the use of IBD therapeutic drugs. Results: A total of 515 patients with IBD were included in the study: 234 with CD, and 281 with UC. Of these, 174 patients (34%) had possible/confirmed COVID-19 of whom 156 (90%) were symptomatic. Main symptoms were fever (65%) and headache (65%); gastrointestinal symptoms occurred in one third of patients and were higher than COVID-19 in general population. The factors associated with having COVID-19 were female gender (OR 1.71, 95%CI: 1.17-2.50); contact at home (OR 5.07, 95%CI: 3.31-7.78) and outside the home (OR 3.14, 95%CI: 2.10-4.71) with a case of COVID-19; work outside of the home (OR 1.87, 95%CI: 1.26-2.78); family history of COVID-19 (OR 2.29, 95%CI 1.58-3.33) use of salicylate (OR 1.71, 95%CI: 1.17-4.28); and asthma (OR 7.10, 95%CI: 1.46-34.57). Conclusion: IBD patients at high risk of COVID-19 infection may need to avoid salicylate therapy but further studies are necessary to confirm this association.